Viatris/$VTRS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Ticker

$VTRS
Sector
Primary listing

Employees

32,000

Viatris Metrics

BasicAdvanced
$12B
-
-$2.92
0.92
$0.48
4.74%

What the Analysts think about Viatris

Analyst ratings (Buy, Hold, Sell) for Viatris stock.

Bulls say / Bears say

Viatris announced that the FDA issued a warning letter and imposed an import alert after inspecting its Indore, India plant in June 2024, leading the company to lower its 2025 revenue forecast by about $500 million and cut adjusted EBITDA guidance by $385 million; shares dropped around 15% the same day, reflecting investor concerns (Hagens Berman)
Viatris’ Phase 3 trial of its MR-139 ophthalmic ointment for blepharitis did not achieve its main goal, marking a major setback for the company’s ophthalmology pipeline, and causing shares to fall 4.1% in premarket trading (Barron’s)
Viatris has agreed to pay up to $335 million over nine years to settle opioid-related claims across the U.S., increasing legal costs and likely putting further pressure on near-term free cash flow (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.

Viatris Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Viatris Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VTRS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs